Pseudomonas vaccination and immunotherapy: An overview

Journal of Burn Care and Rehabilitation

Volumn 22, Issue 5, 2001, Pages 311-320

  Holder, I A ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; DNA VACCINE; OUTER MEMBRANE PROTEIN; PEV 01; POLYSACCHARIDE; PSEUDOGEN; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ARTICLE; BACTERIUM PILUS; FLAGELLUM; GRAM NEGATIVE INFECTION; GUINEA PIG; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RABBIT; RIBOSOME; VACCINATION;

EID: 0034820682     PISSN: 02738481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004630-200109000-00004     Document Type: Article

References (102)

1. Occurrence of serious infections since introduction of antibacterial agents
2. The changing pattern of life-threatening microbial disease
3. Development of Proteus and Pseudomonas infections during antibiotic therapy
4. Fatal Pseudomonas septicemias in burned patients
5. Antibiotic-resistant gram-negative bacilli in a urological ward for male patients during a nine-year period: Relationship to antibiotic consumption
6. Gentamicin resistant Pseudomonas aeruginosa in a burns unit
7. Current use of aminoglycosides
8. Role of Pseudomonas aeruginosa exoenzymes in lung infections of patients with cystic fibrosis
9. Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections
10. Untersuchungen uber die O-antigene von Pseudomonas aeruginosa
11. Serological properties of Pseudomonas aeruginosa. I. Group-specific somatic antigens
12. New immunogenic schema for Pseudomonas aeruginosa based on protective antigens
13. A new antigenic schema and live-cell slide-agglutination procedure for the infrasubspecific, serologic classification of Pseudomonas aeruginosa
14. Isolation and characterization of antigenic components of a new heptavalent pseudomonas vaccine
15. A new polyvalent vaccine
16. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. III. Identity of lethal toxins produced in vitro and in vivo
17. The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. II. Effects of lecithinase and protease
18. Exotoxins of Pseudomonas aeruginosa. III. Characteristics of exotoxin A
19. The lethal events in experimental Pseudomonas aeruginosa infection in mice
20. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Evidence for the in vivo production of a lethal toxin
21. Combined host and specific anti-Pseudomonas directed therapy for Pseudomonas aeruginosa infections in burned mice: Experimental results and theoretic consideration
22. Direct evidence for the presence of lipopolysaccharide components in a Pseudomonas ribosomal vaccine
23. Bacterial motility: A component in experimental Pseudomonas aeruginosa burn wound sepsis
24. Serological properties of Pseudomonas aeruginosa. II. Type-specific thermolabile (flagellar) antigens
25. Flagella specific H antigenic schema of Pseudomonas aeruginosa
26. Role of pili in the adherence of Pseudomonas aeruginosa to mouse epidermal cells
27. Pilin-based anti-Pseudomonas vaccines: Latest developments and perspectives
28. Interaction of the receptor binding domains of Pseudomonas aeruginosa pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: Implications for synthetic vaccine design
29. Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa
30. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2
31. Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs
32. Alginate biosynthesis and other unusual characteristics associated with the pathogenesis of Pseudomonas aeruginosa in cystic fibrosis
33. 125I] lactoperoxidase
34. Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies
35. Outer membrane proteins of Pseudomonas aeruginosa serotype strains
36. Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers
37. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers
38. Human immune response to a Pseudomonas aeruginosa outer membrane protein vaccine
39. Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa
40. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans
41. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
42. DNA vaccines-A modern gimmick or a boon to vaccinology
43. Immune response to a hepatitis B DNA vaccine in Aotus monkeys: A comparison of vaccine formulation, route, and method of administration
44. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients
45. Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa or Burkholderia cepacia
46. Type III protein secretion systems in bacterial pathogens of animals and plants
47. Type III secretion systems: Machines to deliver bacterial proteins into eukaryotic cells?
48. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury
49. Type III. Secretion/intoxication system important in virulence of P. aeruginosa infections in burns
50. PcrV immunization protects burned mice from P. aeruginosa infection
51. PcrV immunization enhances survival of burned P. aeruginosa infected mice
52. Use of vaccine and hyperimmune serum for protection against Pseudomonas septicemia
53. Susceptibility of burned mice to Pseudomonas aeruginosa and protection by vaccination
54. Immunization against Pseudomonas aeruginosa
55. Immunological control of Pseudomonas infection in burn patients: A clinical evaluation
56. Immunization against Pseudomonas in infection after thermal injury
57. Pseudomonas aeruginosa vaccine in cancer patients
58. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia
59. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis
60. A new polyvalent Pseudomonas vaccine
61. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients
62. Efficacy of cell wall Pseudomonas aeruginosa vaccines for protection against experimental pneumonia
63. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections
64. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa
65. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids
66. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide
67. Efficacy of ribosomal preparations from Pseudomonas aeruginosa to protect against intravenous Pseudomonas challenge in mice
68. Serotype-non-specific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa
69. Active and passive immunity against Pseudomonas aeruginosa with a ribosomal vaccine and antiserum in C3H/HeJ mice
70. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model
71. Flagella preparations from Pseudomonas aeruginosa: Animal protection studies
72. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: Immunization using divalent flagella preparations
73. Virulence and protection with a flagella vaccine against Pseudomonas aeruginosa infection
74. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infections
75. Inhibitory activity on bacterial motility and in vivo protective activity of human monoclonal antibodies flagella of Pseudomonas aeruginosa
76. Cross-protection by Pseudomonas aeruginosa polysaccharides
77. Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice
78. Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide
79. Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals
80. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections
81. Immunization with Pseudomonas aeruginosa vaccines and adjuvant can modulate the type of inflammatory response subsequent to infection
82. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (Alginate) vaccine
83. Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model
84. Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F
85. Outer membrane protein F (Porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model
86. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection
87. Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli
88. Preservation of pulmonary function by an outer membrane protein F vaccine
89. Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins
90. Ability of synthetic peptides representing epitopes of outer membrane protein F of Pseudomonas aeruginosa to afford protection against P. aeruginosa infection in a murine acute pneumonia model
91. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa
92. Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy
93. Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients
94. Effects of elastase, protease and common antigen (OEP) from Pseudomonas aeruginosa on protection against burns in mice
95. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection
96. Preparation and characterization of a nontoxic polysaccharide-protein conjugate that induces active immunity and passively protective antibody against Pseudomonas aeruginosa immunotype 1 in mice
97. Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine
98. Safety and immunogenicity of a polyvalent Pseudomonas aeruginosa immunotype 50 polysaccharide-toxin A conjugate vaccine effect of a booster dose on antibody levels in humans
99. Use of a purified outer membrane protein F (Porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice
100. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice
101. Immune response following genetic immunization with DNA encoding type B flagellin from Pseudomonas aeruginosa
102. Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A